Radiogenomic signatures associated with genomic assays (Oncotype DX) were identified as independent predictors after adjusting for clinical factors for survival and neoadjuvant chemotherapy response in estrogen receptor–positive breast cancer.
|Original language||English (US)|
|State||Published - Nov 30 2021|
Bibliographical noteKAUST Repository Item: Exported on 2021-12-14
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging